Asset
Belzutifan
Merck & Company Inc. Common Stock (new)
Revenue
| Period | Revenue |
|---|---|
| Q2 2026 | $271.0M |
| Q1 2026 | $199.0M |
| Q4 2025 | $220.0M |
| Q3 2025 | $196.0M |
| Q2 2025 | $162.0M |
| Q1 2025 | $137.0M |
| Q4 2024 | $160.0M |
| Q3 2024 | $139.0M |
| Q2 2024 | $126.0M |
| Q1 2024 | $85.0M |
| Q4 2023 | $72.0M |
| Q3 2023 | $54.0M |
| Q2 2023 | $50.0M |
| Q1 2023 | $42.0M |
| Q4 2022 | $40.0M |
| Q3 2022 | $38.0M |
| Q2 2022 | $27.0M |
| Q1 2022 | $18.0M |
Revenue as reported by this company. A combination product's amount appears on each of its constituent assets, so those figures are not additive. A fourth quarter is the reported full year less nine months, since no filing states one.
Clinical trials (29)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06903715 | phase1 | completed | 2025-03-28 | 2025-05-08 | Merck Sharp & Dohme LLC | A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035) |
| NCT07489495 | phase3 | recruiting | 2026-04-09 | 2030-11-27 | Merck Sharp & Dohme LLC | A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) |
| NCT07227402 | phase3 | recruiting | 2025-11-26 | 2032-02-27 | Merck Sharp & Dohme LLC | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) |
| NCT07793942 | phase2 | not_yet_recruiting | 2026-09-29 | 2028-09-26 | Merck Sharp & Dohme LLC | A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) |
| NCT03445169 | phase1 | completed | 2018-02-23 | 2018-05-26 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 215383 | NDA | MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC |
Marketed products (1)
- WELIREG